Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019, 163(1):1-7 | DOI: 10.5507/bp.2018.084

Telomere dynamics in adult hematological malignancies

Helena Olbertovaa,b, Karla Plevovaa,b, Kamila Stranskaa,b, Sarka Pospisilovaa,b
a Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
b Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

Telomeres are repetitive DNA sequences protecting physical ends of linear chromosomes against degradation and end-to-end chromosomal fusion. Telomeres shorten with each cell division, which regulates the cellular lifespan in somatic cells and limits their renewal capacity. Cancer cells are often able to overcome this physiological barrier and become immortal with unlimited replicative capacity. In this review, we present current knowledge on the role of telomeres in human aging with a focus on their behavior in hematological malignancies of adults. Associations of telomere length to age-related diseases and to the prevention of telomere shortening are also discussed.

Keywords: telomere, telomerase, leukemia, lymphoma, hematooncology, aging

Received: October 30, 2018; Accepted: December 19, 2018; Prepublished online: January 10, 2019; Published: February 18, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Olbertova, H., Plevova, K., Stranska, K., & Pospisilova, S. (2019). Telomere dynamics in adult hematological malignancies. Biomedical papers, 163(1), 1-7. doi: 10.5507/bp.2018.084
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. de Lange T, Shiue L, Myers RM, Cox DR, Naylor SL, Killery AM, Varmus HE. Structure and variability of human chromosome ends. Mol Cell Biol 1990;10(2):518-27. Go to original source... Go to PubMed...
    2. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345(6274):458-60. Go to original source... Go to PubMed...
    3. Henderson ER, Blackburn EH. An overhanging 3' terminus is a conserved feature of telomeres. Mol Cell Biol American Society for Microbiology (ASM); 1989;9(1):345-8. Go to original source... Go to PubMed...
    4. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, de Lange T. Mammalian telomeres end in a large duplex loop. Cell 1999;97(4):503-14. Go to original source... Go to PubMed...
    5. Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J. Telomeric Repeat Containing RNA and RNA Surveillance Factors at Mammalian Chromosome Ends. Science (80- ) 2007;318(5851):798-801. Go to original source... Go to PubMed...
    6. Balk B, Maicher A, Dees M, Klermund J, Luke-Glaser S, Bender K, Luke B. Telomeric RNA-DNA hybrids affect telomere-length dynamics and senescence. Nat Struct Mol Biol 2013;20(10):1199-205. Go to original source... Go to PubMed...
    7. Vannier J-B, Pavicic-Kaltenbrunner V, Petalcorin MIR, Ding H, Boulton SJ. RTEL1 Dismantles T Loops and Counteracts Telomeric G4-DNA to Maintain Telomere Integrity. Cell 2012;149(4):795-806. Go to original source... Go to PubMed...
    8. Wu P, Takai H, de Lange T. Telomeric 3' Overhangs Derive from Resection by Exo1 and Apollo and Fill-In by POT1b-Associated CST. Cell 2012;150(1):39-52. Go to original source... Go to PubMed...
    9. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90(4):785-95. Go to original source... Go to PubMed...
    10. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J. The RNA component of human telomerase. Science 1995;269(5228):1236-41. Go to original source... Go to PubMed...
    11. Dunham MA, Neumann AA, Fasching CL, Reddel RR. Telomere maintenance by recombination in human cells. Nat Genet 2000;26(4):447-50. Go to original source... Go to PubMed...
    12. Heaphy CM, Subhawong AP, Hong S-M, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, Shih I-M, Iacobuzio-Donahue CA, Maitra A, Li QK, Eberhart CG, Taube JM, Rakheja D, Kurman RJ, Wu TC, Roden RB, Argani P, De Marzo AM, Terracciano L, Torbenson M, Meeker AK. Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes. Am J Pathol 2011;179(4):1608-15. Go to original source... Go to PubMed...
    13. Arora R, Lee Y, Wischnewski H, Brun CM, Schwarz T, Azzalin CM. RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells. Nat Commun 2014;5(1):5220. Go to original source... Go to PubMed...
    14. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai E V, Futcher AB, Greider CW, Harley CB. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 1992;89(21):10114-8. Go to original source... Go to PubMed...
    15. Collins K, Mitchell JR. Telomerase in the human organism. Oncogene 2002;21(4):564-79. Go to original source... Go to PubMed...
    16. Wright WE, Shay JW. Telomere Biology in Aging and Cancer. J Am Geriatr Soc 2005;53(9s):S292-S294. Go to original source... Go to PubMed...
    17. Mirabello L, Huang W-Y, Wong JYY, Chatterjee N, Reding D, David Crawford E, De Vivo I, Hayes RB, Savage SA. The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer. Aging Cell 2009;8(4):405-13. Go to original source... Go to PubMed...
    18. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114(12):1752-61. Go to original source... Go to PubMed...
    19. Cherkas LF, Hunkin JL, Kato BS, Richards JB, Gardner JP, Surdulescu GL, Kimura M, Lu X, Spector TD, Aviv A. The Association Between Physical Activity in Leisure Time and Leukocyte Telomere Length. Arch Intern Med 2008;168(2):154. Go to original source... Go to PubMed...
    20. Alberg A. The influence of cigarette smoking on circulating concentrations of antioxidant micronutrients. Toxicology 2002;180(2):121-37. Go to original source... Go to PubMed...
    21. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, Cawthon RM. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci 2004;101(49):17312-5. Go to original source... Go to PubMed...
    22. Rhee DB, Ghosh A, Lu J, Bohr VA, Liu Y. Factors that influence telomeric oxidative base damage and repair by DNA glycosylase OGG1. DNA Repair (Amst) 2011;10(1):34-44. Go to original source... Go to PubMed...
    23. Sanders JL, Newman AB. Telomere Length in Epidemiology: A Biomarker of Aging, Age-Related Disease, Both, or Neither? Epidemiol Rev 2013;35(1):112-31. Go to original source... Go to PubMed...
    24. Hartmann U, Brummendorf T, Balabanov S, Thiede C, Illme T, Schaich M. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica Haematologica; 2005;90(3):307-16. Go to PubMed...
    25. Capraro V, Zane L, Poncet D, Perol D, Galia P, Preudhomme C, Bonnefoy-Berard N, Gilson E, Thomas X, El-Hamri M. Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. Exp Hematol 2011;39(2):195-202.e2. Go to original source... Go to PubMed...
    26. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109(2):431-48. Go to original source... Go to PubMed...
    27. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, Döhner H, Campbell PJ. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med Massachusetts Medical Society; 2016;374(23):2209-21. Go to original source... Go to PubMed...
    28. Gross M, Mkrtchyan H, Glaser M, Fricke HJ, Höffken K, Heller A, Weise A, Liehr T. Delineation of yet unknown cryptic subtelomere aberrations in 50% of acute myeloid leukemia with normal GTG-banding karyotype. Int J Oncol 2009;34(2):417-23.
    29. Boultwood J, Fidler C, Shepherd P, Watkins F, Snowball J, Haynes S, Kusec R, Gaiger A, Littlewood TJ, Peniket AJ, Wainscoat JS. Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia. Am J Hematol 1999;61(1):5-9. Go to original source... Go to PubMed...
    30. Ohyashiki K, Ohyashiki JH, Iwama H, Hayashi S, Shay JW, Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia 1997;11(2):190-4. Go to original source... Go to PubMed...
    31. Boultwood J, Peniket A, Watkins F, Shepherd P, McGale P, Richards S, Fidler C, Littlewood TJ, Wainscoat JS. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood 2000;96(1):358-61. Go to original source...
    32. Brümmendorf TH, Holyoake TL, Rufer N, Barnett MJ, Schulzer M, Eaves CJ, Eaves AC, Lansdorp PM, Wainscoat JS. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood American Society of Hematology 2000;95(6):1883-90. Go to original source...
    33. Samassekou O, Ntwari A, Hébert J, Yan J. Individual telomere lengths in chronic myeloid leukemia. Neoplasia 2009;11(11):1146-54. Go to original source... Go to PubMed...
    34. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391-405. Go to original source... Go to PubMed...
    35. Boultwood J, Fidler C, Kusec R, Rack K, Elliott PJ, Atoyebi O, Chapman R, Oscier DG, Wainscoat JS. Telomere length in myelodysplastic syndromes. Am J Hematol 1997;56(4):266-71. Go to original source... Go to PubMed...
    36. Rollison DE, Epling-Burnette PK, Park JY, Lee J-H, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, MelÉndez-Santiago J, Fulp W, Komrokji R, Lancet J, List AF. Telomere length in myelodysplastic syndromes. Leuk Lymphoma 2011;52(8):1528-36. Go to original source... Go to PubMed...
    37. Lange K, Holm L, Vang Nielsen K, Hahn A, Hofmann W, Kreipe H, Schlegelberger B, GÃhring G. Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes, Chromosom Cancer 2009;49(3):n/a-n/a. Go to original source... Go to PubMed...
    38. Colla S, Ong DST, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Multani AS, Jiang S, Hua S, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D'Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LJN, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DePinho RA. Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome. Cancer Cell 2015;27(5):644-57. Go to original source... Go to PubMed...
    39. Gürkan E, Tanriverdi K, Başlamişli F. Telomerase activity in myelodysplastic syndromes. Leuk Res 2005;29(10):1131-9. Go to original source... Go to PubMed...
    40. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94(6):1848-54. Go to original source...
    41. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94(6):1840-7. Go to original source...
    42. Damle RN, Batliwalla FM, Ghiotto F, Valetto A, Albesiano E, Sison C, Allen SL, Kolitz J, Vinciguerra VP, Kudalkar P, Wasil T, Rai KR, Ferrarini M, Gregersen PK, Chiorazzi N. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 2004;103(2):375-82. Go to original source... Go to PubMed...
    43. Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, Deambrogi C, Ricca I, Rocci A, Ferrero S, Bernocco E, Capello D, De Paoli L, Bergui L, Boi M, Omedè P, Massaia M, Tarella C, Passera R, Boccadoro M, Gaidano G, Ladetto M. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia 2009;23(6):1062-72. Go to original source... Go to PubMed...
    44. Strefford JC, Kadalayil L, Forster J, Rose-Zerilli MJJ, Parker A, Lin TT, Heppel N, Norris K, Gardiner A, Davies Z, Gonzalez de Castro D, Else M, Steele AJ, Parker H, Stankovic T, Pepper C, Fegan C, Baird D, Collins A, Catovsky D, Oscier DG. Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Leukemia 2015;29(12):2411-4. Go to original source... Go to PubMed...
    45. Dos Santos P, Panero J, Palau Nagore V, Stanganelli C, Bezares RF, Slavutsky I. Telomere shortening associated with increased genomic complexity in chronic lymphocytic leukemia. Tumor Biol 2015;36(11):8317-24. Go to original source... Go to PubMed...
    46. Britt-Compton B, Lin TT, Ahmed G, Weston V, Jones RE, Fegan C, Oscier DG, Stankovic T, Pepper C, Baird DM. Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage. Leukemia 2012;26(4):826-30. Go to original source... Go to PubMed...
    47. Navrkalova V, Young E, Baliakas P, Radova L, Sutton L-A, Plevova K, Mansouri L, Ljungström V, Ntoufa S, Davis Z, Juliusson G, Smedby KE, Belessi C, Panagiotidis P, Touloumenidou T, Davi F, Langerak AW, Ghia P, Strefford JC, Oscier D, Mayer J, Stamatopoulos K, Pospisilova S, Rosenquist R, Trbusek M. ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres. Haematologica 2016;101(9):e369-73. Go to original source... Go to PubMed...
    48. Roos G, Krober A, Grabowski P, Kienle D, Buhler A, Dohner H, Rosenquist R, Stilgenbauer S. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 2008;111(4):2246-52. Go to original source... Go to PubMed...
    49. Mansouri L, Grabowski P, Degerman S, Svenson U, Gunnarsson R, Cahill N, Smedby KE, Geisler C, Juliusson G, Roos G, Rosenquist R. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. Am J Hematol 2013;88(8):647-51. Go to original source... Go to PubMed...
    50. Rampazzo E, Bonaldi L, Trentin L, Visco C, Keppel S, Giunco S, Frezzato F, Facco M, Novella E, Giaretta I, Del Bianco P, Semenzato G, De Rossi A. Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica 2012;97(1):56-63. Go to original source... Go to PubMed...
    51. Terrin L, Trentin L, Degan M, Corradini I, Bertorelle R, Carli P, Maschio N, Bo MD, Noventa F, Gattei V, Semenzato G, De Rossi A. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia 2007;21(5):965-72. Go to original source... Go to PubMed...
    52. Norrback KF, Dahlenborg K, Carlsson R, Roos G. Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas. Blood 1996;88(1):222-9. Go to original source...
    53. Ramsay AJ, Quesada V, Foronda M, Conde L, Martínez-Trillos A, Villamor N, Rodríguez D, Kwarciak A, Garabaya C, Gallardo M, López-Guerra M, López-Guillermo A, Puente XS, Blasco MA, Campo E, López-Otín C. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet 2013;45(5):526-30. Go to original source... Go to PubMed...
    54. Poncet D, Belleville A, t'Kint de Roodenbeke C, Roborel de Climens A, Ben Simon E, Merle-Beral H, Callet-Bauchu E, Salles G, Sabatier L, Delic J, Gilson E. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood 2008;111(4):2388-91. Go to original source... Go to PubMed...
    55. Augereau A, T'kint de Roodenbeke C, Simonet T, Bauwens S, Horard B, Callanan M, Leroux D, Jallades L, Salles G, Gilson E, Poncet D. Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation. Blood 2011;118(5):1316-22. Go to original source... Go to PubMed...
    56. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403(6769):503-11. Go to original source... Go to PubMed...
    57. Lenz G, Wright GW, Emre NCT, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci 2008;105(36):13520-5. Go to original source... Go to PubMed...
    58. Walsh SH, Grabowski P, Berglund M, Thunberg U, Thorsélius M, Tobin G, Åleskog A, Karlsson K, Sundström C, Laurell A, Enblad G, Rosenquist R, Roos G. Telomere length and correlation with histopathogenesis in B-cell leukemias/lymphomas. Eur J Haematol 2007;78(4):283-9. Go to original source... Go to PubMed...
    59. Zhang J, Jima D, Moffitt AB, Liu Q, Czader M, Hsi ED, Fedoriw Y, Dunphy CH, Richards KL, Gill JI, Sun Z, Love C, Scotland P, Lock E, Levy S, Hsu DS, Dunson D, Dave SS. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood 2014;123(19):2988-96. Go to original source... Go to PubMed...
    60. Bea S, Valdes-Mas R, Navarro A, Salaverria I, Martin-Garcia D, Jares P, Gine E, Pinyol M, Royo C, Nadeu F, Conde L, Juan M, Clot G, Vizan P, Di Croce L, Puente DA, Lopez-Guerra M, Moros A, Roue G, Aymerich M, Villamor N, Colomo L, Martinez A, Valera A, Martin-Subero JI, Amador V, Hernandez L, Rozman M, Enjuanes A, Forcada P, Muntanola A, Hartmann EM, Calasanz MJ, Rosenwald A, Ott G, Hernandez-Rivas JM, Klapper W, Siebert R, Wiestner A, Wilson WH, Colomer D, Lopez-Guillermo A, Lopez-Otin C, Puente XS, Campo E. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci 2013;110(45):18250-5. Go to original source... Go to PubMed...
    61. Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B, Gunawardana J, Jenkins C, Cochrane C, Ben-Neriah S, Tan K, Morin RD, Opat S, Sehn LH, Connors JM, Marra MA, Weng AP, Steidl C, Gascoyne RD. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012;119(9):1963-71. Go to original source... Go to PubMed...
    62. Jebaraj BMC, Kienle D, Lechel A, Mertens D, Heuberger M, Ott G, Rosenwald A, Barth TFE, Moller P, Zenz T, Dohner H, Stilgenbauer S. Telomere length in mantle cell lymphoma. Blood 2013;121(7):1184-7. Go to original source... Go to PubMed...
    63. Vaandrager JW, Schuuring E, Raap T, Philippo K, Kleiverda K, Kluin P. Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes. Genes Chromosomes Cancer 2000;27(1):85-94. Go to original source...
    64. Ladetto M, Compagno M, Ricca I, Pagano M, Rocci A, Astolfi M, Drandi D, di Celle PF, Dell'Aquila M, Mantoan B, Vallet S, Pagliano G, De Marco F, Francese R, Santo L, Cuttica A, Marinone C, Boccadoro M, Tarella C. Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. Blood 2004;103(12):4644-9. Go to original source... Go to PubMed...
    65. Klapper W, Krams M, Qian W, Janssen D, Parwaresch R. Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation. Br J Cancer Nature Publishing Group; 2003;89(4):713-9. Go to original source... Go to PubMed...
    66. Küppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, Hansmann ML. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A National Academy of Sciences; 1994;91(23):10962-6. Go to original source... Go to PubMed...
    67. M'kacher R, Bennaceur-Griscelli A, Girinsky T, Koscielny S, Delhommeau F, Dossou J, Violot D, Leclercq E, Courtier MH, Béron-Gaillard N, Assaf E, Ribrag V, Bourhis J, Feneux D, Bernheim A, Parmentier C, Carde P. Telomere Shortening and Associated Chromosomal Instability in Peripheral Blood Lymphocytes of Patients With Hodgkin's Lymphoma Prior to Any Treatment Are Predictive of Second Cancers. Int J Radiat Oncol 2007;68(2):465-71. Go to original source... Go to PubMed...
    68. Knecht H, Kongruttanachok N, Sawan B, Brossard J, Prévost S, Turcotte E, Lichtensztejn Z, Lichtensztejn D, Mai S. Three-dimensional Telomere Signatures of Hodgkin- and Reed-Sternberg Cells at Diagnosis Identify Patients with Poor Response to Conventional Chemotherapy. Transl Oncol Neoplasia Press; 2012;5(4):269-77. Go to original source... Go to PubMed...
    69. Norrback KF, Enblad G, Erlanson M, Sundström C, Roos G. Telomerase activity in Hodgkin's disease. Blood 1998;92(2):567-73. Go to original source...
    70. Brousset P, Chaouche N, Saati T Al, Zenou RC, Delsol G. Telomerase Activity in Hodgkin's Disease. Leuk Lymphoma 1998;30(1-2):189-92. Go to original source... Go to PubMed...
    71. M'Kacher R, Cuceu C, Al Jawhari M, Morat L, Frenzel M, Shim G, Lenain A, Hempel W, Junker S, Girinsky T, Colicchio B, Dieterlen A, Heidingsfelder L, Borie C, Oudrhiri N, Bennaceur-Griscelli A, Moralès O, Renaud S, Van de Wyngaert Z, Jeandidier E, Delhem N, Carde P. The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes. Cancers (Basel) 2018;10(6):169. Go to original source... Go to PubMed...
    72. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ. A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance. N Engl J Med 2002;346(8):564-9. Go to original source... Go to PubMed...
    73. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121(5):749-57. Go to original source... Go to PubMed...
    74. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar S V, Durie BGM, International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia 2012;26(1):149-57. Go to original source... Go to PubMed...
    75. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp M-J, Harousseau J-L, Minvielle S, Bataille R, Intergroupe Francophone du Myélome. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002;99(6):2185-91. Go to original source... Go to PubMed...
    76. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa A-M, Sotto J-J, Wetterwald M, Dumontet C, Fuzibet J-G, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau J-L, Facon T, Mathiot C. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109(8):3489-95. Go to original source... Go to PubMed...
    77. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet J-P, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471(7339):467-72. Go to original source... Go to PubMed...
    78. Hyatt S, Jones RE, Heppel NH, Grimstead JW, Fegan C, Jackson GH, Hills R, Allan JM, Pratt G, Pepper C, Baird DM. Telomere length is a critical determinant for survival in multiple myeloma. Br J Haematol 2017;178(1):94-8. Go to original source... Go to PubMed...
    79. Wu K-D, Orme LM, Shaughnessy J, Jacobson J, Barlogie B, Moore MAS. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 2003;101(>12):4982-9. Go to original source... Go to PubMed...
    80. Brennan SK, Wang Q, Tressler R, Harley C, Go N, Bassett E, Huff CA, Jones RJ, Matsui W. Telomerase Inhibition Targets Clonogenic Multiple Myeloma Cells through Telomere Length-Dependent and Independent Mechanisms. Swarbrick A, editor. PLoS One 2010;5(9):e12487. Go to original source... Go to PubMed...
    81. Engelhardt M, Mackenzie K, Drullinsky P, Silver RT, Moore MA. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res 2000;60(3):610-7.

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content